A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer

Abstract Background Although clinical trials have investigated the addition of pembrolizumab to chemotherapy for non‐small cell lung cancer, none have investigated the addition of chemotherapy to pembrolizumab. Methods We conducted a retrospective study of 71 NSCLC patients including 33 treated with...

Full description

Bibliographic Details
Main Authors: Taisuke Isono, Naho Kagiyama, Shun Shibata, Hitomi Nakajima, Yuma Matsui, Kenji Takano, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Yotaro Takaku, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayanagi
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Thoracic Cancer
Subjects:
adverse event
combination therapy
immune checkpoint inhibitor
overall survival
treatment discontinuation
Online Access:https://doi.org/10.1111/1759-7714.13915

Internet

https://doi.org/10.1111/1759-7714.13915

Similar Items